within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AR20_EmtricitabineTenofovirAlafenamideAndBictegravir;

model EmtricitabineTenofovirAlafenamideAndBictegravir
  extends Pharmacolibrary.Drugs.ATC.J.J05AR20;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>J05AR20</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Emtricitabine, tenofovir alafenamide, and bictegravir is a fixed-dose combination antiretroviral medication used in the treatment of HIV-1 infection in adults and pediatric patients. It acts by inhibiting viral reverse transcriptase (emtricitabine, tenofovir) and integrase (bictegravir), preventing the replication of HIV-1. The combination is approved and widely used today.</p><h4>Pharmacokinetics</h4><p>Mean pharmacokinetic parameters reported for healthy HIV-negative adult subjects receiving the fixed-dose combination as a single oral tablet once daily under fasting conditions.</p><h4>References</h4><ol><li><p>Bruzzesi, E, et al., &amp; Castagna, A (2024). Pharmacokinetic evaluation of bictegravir + emtricitabine + tenofovir alafenamide in HIV treatment. <i>Expert opinion on drug metabolism &amp; toxicology</i> None 1–8. DOI:<a href=&quot;https://doi.org/10.1080/17425255.2024.2428820&quot;>10.1080/17425255.2024.2428820</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39530796/&quot;>https://pubmed.ncbi.nlm.nih.gov/39530796</a></p></li><li><p>Lacombe-Duncan, A, et al., &amp; Loutfy, M (2024). Protocol of a drug-drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV. <i>British journal of clinical pharmacology</i> 90(10) 2349–2359. DOI:<a href=&quot;https://doi.org/10.1111/bcp.16162&quot;>10.1111/bcp.16162</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38992893/&quot;>https://pubmed.ncbi.nlm.nih.gov/38992893</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end EmtricitabineTenofovirAlafenamideAndBictegravir;
